More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds

More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds

Show other versions (1)

The use of tyrosine kinase inhibitors (TKIs) in the treatment of solid tumors is the expected standard of care for many types of tumors. Since the description of signal transduction pathways, followed by the development of small molecules designed to inhibit those pathways, there has been significan...

Full description

Bibliographic Details
Main Author: Maria Vergoulidou
Format: Article
Language:English
Published: SAGE Publishing 2015-01-01
Series:Biomarker Insights
Online Access:https://doi.org/10.4137/BMI.S22436
id doaj-82604e5e56894d53a0b516029d9a5dc3
record_format Article
spelling doaj-82604e5e56894d53a0b516029d9a5dc32020-11-25T03:40:12ZengSAGE PublishingBiomarker Insights1177-27192015-01-0110s310.4137/BMI.S22436More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future HoldsMaria Vergoulidou0Department of Haematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charitè Medical University, Berlin, Germany.The use of tyrosine kinase inhibitors (TKIs) in the treatment of solid tumors is the expected standard of care for many types of tumors. Since the description of signal transduction pathways, followed by the development of small molecules designed to inhibit those pathways, there has been significant improvement not only in progression-free survival and overall survival but also in aiming toward chemotherapy-free treatment of solid tumors to maximize quality of life. This article reviews available TKIs and discusses toxicity, dosing, and resistance.https://doi.org/10.4137/BMI.S22436
collection DOAJ
language English
format Article
sources DOAJ
author Maria Vergoulidou
spellingShingle Maria Vergoulidou
More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds
Biomarker Insights
author_facet Maria Vergoulidou
author_sort Maria Vergoulidou
title More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds
title_short More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds
title_full More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds
title_fullStr More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds
title_full_unstemmed More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds
title_sort more than a decade of tyrosine kinase inhibitors in the treatment of solid tumors: what we have learned and what the future holds
publisher SAGE Publishing
series Biomarker Insights
issn 1177-2719
publishDate 2015-01-01
description The use of tyrosine kinase inhibitors (TKIs) in the treatment of solid tumors is the expected standard of care for many types of tumors. Since the description of signal transduction pathways, followed by the development of small molecules designed to inhibit those pathways, there has been significant improvement not only in progression-free survival and overall survival but also in aiming toward chemotherapy-free treatment of solid tumors to maximize quality of life. This article reviews available TKIs and discusses toxicity, dosing, and resistance.
url https://doi.org/10.4137/BMI.S22436
work_keys_str_mv AT mariavergoulidou morethanadecadeoftyrosinekinaseinhibitorsinthetreatmentofsolidtumorswhatwehavelearnedandwhatthefutureholds
_version_ 1724535619252649984

Similar Items